Sunshine Biopharma Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 13, 2019 and accepted by EDGAR at Nov 13, 2019, 14:54 ET.
Management's discussion and analysis
As filed, 26,266 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.
Overview and History
We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.” Until October 2009, our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.
In October 2009, we acquired Sunshine Biopharma, Inc., a Colorado corporation holding an exclusive license (the “License”) to a new anticancer drug bearing the laboratory name, Adva-27a. As a result of this transaction we changed our name to “Sunshine Biopharma, Inc.” and our officers and directors resigned their positions with us and were replaced by Sunshine Biopharma, Inc.’s management at the time, including our current CEO, Dr. Steve N. Slilaty, and our current CFO, Camille Sebaaly each of whom remain part of our current management. Our principal business became that of a pharmaceutical company focusing on the development of our licensed Adva-27a anticancer compound. In December 2015 we acquired all issued and pending patents pertaining to our Adva-27a technology and terminated the License.
In July 2014, we formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for the treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia). We have applied for and are currently awaiting the issuance by Health Canada of a Drug Establishment License and a Drug Identification Number for each of our four (4) generic products in order to begin marketing of the same.
In January 2018, we acquired Atlas Pharma Inc. (“Atlas”), a Canadian privately held analytical chemistry company offering sample testing services to the pharmaceutical and other industrial sectors. Effective April 1, 2019, we assigned all of our interest in the Atlas securities back to the seller in exchange for the Atlas related debt.
In March 2018, we formed NOX Pharmaceuticals, Inc., a Colorado corporation, and assigned all of our interest in our Adva-27a anticancer compound to that company. NOX Pharmaceuticals, Inc.’s mission is to research, develop and commercialize proprietary drugs including Adva-27a.
In December 2018, we completed the development of a new nutritional supplement which we trademarked Essential 9tm. This nutritional supplement is an over-the-counter tablet comprised of the nine essential amino acids which the human body cannot synthesize. Essential 9tm has been authorized for marketing by Health Canada under NPN 80089663.
Effective February 1, 2019, we completed a 20 to 1 reverse split of our $0.001 par value Common Stock reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “Reverse Stock Split”). All references in this report to our issued and outstanding Common Stock as well as the price per share of Common Stock are presented on a retroactive post Reverse Stock Split basis.
On March 12, 2019 Essential 9tm became available for sale on Amazon.ca and later on Amazon.com in the United States and elsewhere around the world. On March 23, 2019 we recorded our first revenues of Essential 9tm sales.
On April 30, 2019, we were issued United States Patent Number: 10,272,065, a new patent extending proprietary coverage of our Adva-27a anticancer drug until 2033.
Our principal place of business is located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. Our phone number is (514) 426-6161and our website address is www.sunshinebiopharma.com (http://www.sunshinebiopharma.com).
We have not been subject to any bankruptcy, receivership or similar proceeding.
Plan of Operation
Despite the fact that we currently are generating revenue, we have elected to include a Plan of Operation to discuss our ongoing business activities.
Proprietary Drug Development Operations
Since inception, our proprietary drug development activities have been focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Numbers 8,236,935 and 10,272,065.
Figure 1
Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin (see Figure 1). Another derivative of Podophyllotoxin, called Etoposide, is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding enzyme, Topoisomerase II. Unlike Etoposide, and other anti-tumor drugs currently in use, Adva-27a is able to destroy Multidrug Resistant Cancer cells. Adva-27a is the only compound known today that is capable of destroying Multidrug Resistant Cancer. In addition, Adva-27a has been shown to have distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side studies using Multidrug Resistant Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly greater cell killing activity (see Figure 2).
Figure 2
Our preclinical studies to date have shown that:
Adva-27a is effective at killing different types of Multidrug Resistant cancer cells, including Pancreatic Cancer Cells (Panc-1), Breast Cancer Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells (H69AR), and Uterine Sarcoma Cells (MES-SA/Dx5).
Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.
Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number has recently been reduce to 1.44 micromolar as a result of resolving the two isomeric forms of Adva-27a).
Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.
Adva-27a does not inhibit tubulin assembly.
These and other preclinical data have been published in ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment. The publication which is entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH 32: 4423-4432 (2012)] is available on our website at www.sunshinebiopharma.com (http://www.sunshinebiopharma.com).
We have been delayed in our clinical development program due to lack of funding. Our fund raising efforts are continuing and as soon as adequate financing is in place we will continue our clinical development program of Adva-27a by conducting the following next sequence of steps:
GMP Manufacturing of 2 kilogram for use in IND-Enabling Studies and Phase I Clinical Trials
IND-Enabling Studies
Regulatory Filing (Fast-Track Status Anticipated)
Phase I Clinical Trials (Pancreatic Cancer Indication)
Adva-27a’s initial indication will be Pancreatic Cancer for which there are currently little or no treatment options available. We are planning to conduct our clinical trials at McGill University’s Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will employ FDA standards at all levels.
According to the American Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. While particularly effective against Multidrug Resistant Cancer, we believe Adva-27a can potentially treat all cancer types as it is a general chemotherapy drug. We believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies to buyout or license our drug. However, there are no assurances that our Phase I Trials will be successful, or if successful, that any pharmaceutical companies will make an acceptable offer to us. In the event we do not consummate such a transaction, we will require significant capital in order to manufacture and market our new drug. The following, Figure 3, is a space-filling molecular model of our Adva-27a.
Figure 3
Generic Pharmaceuticals Operations
In 2016, our Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), signed Licensing Agreements with a major pharmaceutical company for four prescription generic drugs for the treatment of Breast Cancer, Prostate Cancer and Enlarged Prostate. We have since been working towards securing regulatory approval to commence marketing these pharmaceutical products under our own, Sunshine Biopharma, label. These four generic products are as follows:
Anastrozole (brand name Arimidex® by AstraZeneca) for treatment of Breast Cancer;
Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer;
Bicalutamide (brand name Casodex® by AstraZeneca) for treatment of Prostate Cancer;
Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)
Figure 4 below shows a draft of our Generic Pharmaceuticals label using Anastrozole as an example.
Figure 4
We are currently looking into a number of additional Generic Pharmaceuticals for possible in-licensing. No assurances can be provided that we will acquire the rights to all or any of these generic drugs. We believe that a larger product portfolio will provide us with more opportunities and a greater reach into the marketplace. We hope to further build our Generic Pharmaceuticals portfolio over time. There are no assurances this will occur.
Various publicly available sources indicate that the worldwide sales of generic pharmaceuticals are approximately $250 billion per year. In the United States and Canada, the sales of generic pharmaceuticals are approximately $70 billion and $7 billion, respectively. The generic pharmaceuticals business is very competitive. There are several multinational players in the field including Teva (Israel), Novartis - Sandoz (Switzerland), Hospira (USA), Mylan (Netherlands), Sanofi (France), Fresenius Kabi (Germany) and Pharmascience (Canada). While no assurances can be provided, with our offering of Canadian approved products we believe that we will be able to access a small percentage of the generic pharmaceuticals marketplace.
Nutritional Supplements Operations
In December 2018, we completed the development of Essential 9tm, the first in a line of essential micronutrients products that we are planning to launch. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma Inc. to manufacture and sell the Essential 9tm product. Our Essential 9tm dietary supplement tablets contain a balanced formula of the 9 Essential Amino Acids that the human body cannot make. Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9tm provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9tm is currently available on Amazon.com, Amazon.ca and soon other Amazon sites. Figure 5 below shows our 60-Tablet Essential 9tm product.
Figure 5
Results Of Operations
Comparison of Results of Operations for the Nine Months ended September 30, 2019 and 2018
During the nine months ended September 30, 2019, we generated revenues of $10,565 from the sale of products generated by our Nutritional Supplements Operations which we launched in March 2019. The direct cost for generating these revenues was $6,865. We did not generate any revenues during the comparable period in 2018.
General and Administrative Expenses during the nine months ended September 30, 2019 was $394,746, compared to $1,020,579 during the nine months ended September 30, 2018, a decrease of $625,833. The reason for this relatively large decrease was an effort to reduce expenses across the board. Specifically, executive compensation decreased by $601,879, accounting by $37,031, legal by $31,560 and office by $10,649. The only category that saw an increase was consulting expenses which increased by $42,438 as a result of the launching of our Nutritional Supplements products and our continuing effort to raise capital to fund our Proprietary Drug Development program. In addition, we incurred $15,204 in research and development (R&D) expenses during the nine months ended September 30, 2019 compared to no R&D expenses incurred during the similar period in 2018.
We incurred $185,814 in losses arising from debt conversion during the nine months ended September 30, 2019, compared to $685,348 in losses from debt conversion during the similar period in 2018. We also incurred $92,486 in interest expense during the nine months ended September 30, 2019, compared to $115,910 in interest expense during the similar period in 2018. The decrease in both of these two expense categories was a result of some convertible notes having been paid off or reduced prior to maturity. In addition, we incurred a loss of $582,237 during the nine months ended September 30, 2019, compared to $8,847 in losses from discontinued operations during the similar period in 2018 as a result of termination of our Analytical Chemistry Services Operations and sale of Atlas Pharma Inc.
As a result, we incurred a Net Loss of $1,263,673 ($0.01 per share) for the nine month period ended September 30, 2019, compared to a Net Loss of $1,817,500 ($0.04 per share) during the nine month period ended September 30, 2018.
Comparison of Results of Operations for the Three Months Ended September 30, 2019 and 2018
For the three months ended September 30, 2019, we generated $7,326 in revenues, compared to no revenues for the same three months period of 2018. All of these revenues were generated from our newly launched Nutritional Supplements Operations. The direct cost for generating these revenues was $5,293.
General and Administrative Expenses during the three month period ended September 30, 2019 were $204,673, compared to General and Administrative Expenses of $288,825 incurred during the three month period ended September 30, 2018, a decrease of $84,152. The reason for this decrease was an effort to reduce expenses across the board. Specifically, executive compensation decreased by $121,400, office by $19,925 and legal by $11,444. The two categories that saw an increase were accounting which increased by $5,929 and consulting by $48,222 as a result of the launching of our Nutritional Supplements products and our continuing effort to raise capital to fund our Proprietary Drug Development program. In addition, we incurred $15,204 in R&D expenses during the three months ended September 30, 2019 compared to no R&D expenses incurred during the similar period in 2018.
We incurred $27,847 in interest expense during the three months ended September 30, 2019, compared to $20,546 in interest expense during the similar period in 2018. We also incurred $120,720 in losses arising from debt conversion during the three months ended September 30, 2019, compared to $591,763 in losses from debt conversion during the similar period in 2018. Both of these decreases were a result of decreased borrowings or prepayment of principal balances prior to maturity. In addition, we incurred a loss of $-0- during the three months ended September 30, 2019, compared to $5,278 in income from discontinued operations during the similar period in 2018 as a result of termination of our Analytical Chemistry Services Operations and sale of Atlas Pharma Inc.
As a result, we incurred a Net Loss of $350,241 ($0.00 per share) for the three month period ended September 30, 2019, compared to a Net Loss of $907,556 ($0.02 per share) during the three month period ended September 30, 2018.
Liquidity and Capital Resources
As of September 30, 2019, we had cash or cash equivalents of $81,973.
Net cash used in Operating Activities was $367,959 during the nine month period ended September 30, 2019, compared to $396,759 for the nine month period ended September 30, 2018. We anticipate that overhead costs and other expenses will increase in the future as we move forward with our Proprietary Drug Development activities and expansion of our Generic Pharmaceuticals, and Nutritional Supplements operations as discussed above.
Cash flows provided by Financing Activities were $352,100 for the nine month period ended September 30, 2019, compared to $354,853 during the nine months ended September 30, 2018. Cash Flows used in Investing Activities were $14,416 for the nine month period ended September 30, 2019 compared to $22,370 during the same nine month period in 2018.
During the nine months ended September 30, 2019, we issued a total of 225,773,660 shares of $0.001 par value Common Stock for the conversion of outstanding notes payable, reducing the debt by $241,160 and interest payable by $11,402 and generating a loss on conversion of $221,813.
During the nine months ended September 30, 2019, we entered into the following new debt arrangements:
On January 8, 2019, we received net proceeds of $50,500 in exchange for a note payable having a face value of $54,000 and accruing interest at the rate of 8% per annum. The note, due on January 8, 2020, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
On January 10, 2019, we received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on October 10, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Through September 2019, the holder of this note elected to convert a total of $40,660 in principal and $1,693 in accrued interest into 32,096,307 shares of $0.001 par value Common Stock valued at $75,469 leaving a principal balance of $-0- and incurring a loss on conversion of $33,116.
On February 5, 2019, we received net proceeds of $35,000 in exchange for a note payable having a face value of $37,450 and accruing interest at the rate of 8% per annum. The note, due on October 10, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
On February 11, 2019, we received net proceeds of $50,000 in exchange for a note payable having a face value of $52,000 and accruing interest at the rate of 8% per annum. The note, due on November 30, 2019 is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Through September 2019 the holder of this note elected to convert a total of $52,000 in principal and $2,080 in accrued interest into 45,763,500 shares of $0.001 par value Common Stock valued at $81,990 leaving a principal balance of $-0- and incurring a loss on conversion of $27,910.
On March 18, 2019, we received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on December 18, 2019 is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Through September 2019 the holder of this note elected to convert a total of $11,500 in principal into 12,945,591 shares of $0.001 par value Common Stock valued at $22,008 leaving a principal balance of $29,160 and incurring a loss on conversion of $10,508.
On March 18, 2019, we received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on December 18, 2019 is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
On July 2, 2019, we received net proceeds of $38,000 in exchange for a note payable having a face value of $40,000 and accruing interest at the rate of 8% per annum. The note, due on April 30, 2020 and is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
On July 26, 2019, we received net proceeds of $47,500 in exchange for a note payable having a face value of $50,000 and accruing interest at the rate of 8% per annum. The note, due on July 26, 2020 and is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
On September 12, 2019, we received net proceeds of $41,000 in exchange for a note payable having a face value of $43,000 and accruing interest at the rate of 8% per annum. The note, due on July 15, 2020 and is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
We are not generating adequate revenues from our operations to fully implement our business plan as set forth herein. As a result, our future success will depend on the future availability of financing, among other things. Such financing will be required to enable us to expand our Nutritional Supplements Business and further develop our Generic Pharmaceuticals Operations and Proprietary Drug Development Program. We intend to raise funds through private placements of our Common Stock and/or debt financing. We estimate that we will require approximately $7 million (approximately $2 million for the Nutritional Supplements and Generic Pharmaceuticals Operations and approximately $5 million for the Proprietary Drug Development Program) to fully implement our business plan in the future and there are no assurances that we will be able to raise this capital. Our inability to obtain sufficient funds from external sources when needed will have a material adverse effect on our plan of operation, results of operations and financial condition. Our plan is to fund our Proprietary Drug Development Program through the sales of Generic Drugs and Nutritional Supplements if we are unable to find any additional financing. There are also no assurances that we will generate sufficient revenues and profits from our products sales program to accomplish these objectives.
Our cost of operations is expected to increase as we move forward with implementation of our business plan. We do not have sufficient funds to cover the anticipated increase in the relevant expenses. We need to raise additional capital in order to continue our existing operations and finance our expansion plans for the next year. If we are successful in raising additional funds, we expect our operations and business efforts to continue and expand. There are no assurances this will occur.
Subsequent Events
On October 1, 2019 the holder of a note payable dated December 31, 2018 elected to convert $30,000 in principal into 30,000,000 shares of Common Stock leaving a principal balance of $106,744.
On October 1 and 17, 2019, the holder of a note payable dated March 18, 2019 elected to convert a total of $28,594 in principal into 30,526,493 shares of Common Stock leaving a principal balance of $12,066.
On October 16, 2019 the holder of a note payable dated October 23, 2018 elected to convert a total of $6,000 in principal and $469 in accrued interest into 7,282,716 shares of Common Stock leaving a principal balance of $-0-.
On October 23 and November 7, 2019, the holder of a note payable dated December 24, 2018, elected to convert a total of $28,000 in principal and $1,902 in accrued interest into 42,228,183 shares of Common Stock leaving a principal balance of $59,000.
On November 4 and 6, 2019, the holder of a note payable dated March 18, 2019, elected to convert a total of $17,500 in principal and $1,967 in accrued interest into 32,668,293 shares of Common Stock leaving a principal balance of $11,660.
Off Balance Sheet Arrangements
None
Market risk
As filed, 126 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.
Controls and procedures
As filed, 4,410 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures – Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Report.
These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO to allow timely decisions regarding required disclosure.
Based on this evaluation, our CEO and CFO have concluded that our disclosure controls and procedures were not effective as of September 30, 2019, at reasonable assurance level, for the following reasons:
Ineffective control environment and lack of qualified full-time CFO who has SEC experience to focus on our financial affairs;
Lack of qualified and sufficient personnel, and processes to adequately and timely identify making any and all required public disclosures;
Deficiencies in the period-end reporting process and accounting policies;
Inadequate internal controls over the application of new accounting principles or the application of existing accounting principles to new transactions;
Inadequate internal controls relating to the authorization, recognition, capture, and review of transactions, facts, circumstances, and events that could have a material impact on the company’s financial reporting process;
Deficient revenue recognition policies;
Inadequate internal controls with respect to inventory transactions; and
Improper and lack of timely accounting for accruals such as prepaid expenses, accounts payable and accrued liabilities.
Our Board of Directors has assigned a priority to the short-term and long-term improvement of our internal control over financial reporting. We are reviewing various potential solutions to remedy the processes that would eliminate the issues that may arise due to the absence of separation of duties within the financial reporting functions.
We believe that our financial statements presented in this quarterly report on Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.
Inherent Limitations – Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.
Changes in Internal Control over Financial Reporting – There were no changes in our internal control over financial reporting during the nine month period ended September 30, 2019, which were identified in conjunction with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 126 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $7.3k | us-gaap:Revenues |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $10.6k | us-gaap:Revenues |
| Cost of revenue | 3 months2019-07-01 to 2019-09-30 | $5.3k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2019-01-01 to 2019-09-30 | $6.9k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-07-01 to 2019-09-30 | $2.0k | us-gaap:GrossProfit |
| Gross profit | 9 months2019-01-01 to 2019-09-30 | $3.7k | us-gaap:GrossProfit |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $15.2k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $15.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$202.6k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$391.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-07-01 to 2019-09-30 | $27.8k | us-gaap:InterestExpense |
| Interest expense | 9 months2019-01-01 to 2019-09-30 | $92.5k | us-gaap:InterestExpense |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$350.2k | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$1.3m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2019-07-01 to 2019-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2019-01-01 to 2019-09-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$368.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $0 | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2019-09-30 | $82.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $110.5k | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $146.3k | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $889.2k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $889.2k | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | −$742.9k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001654954-19-012832. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.